Csl Limited · ASX:CSL
Csl — Shareholder Meeting (October 2005)
24 slides from Csl's shareholder meeting presentation, Oct 12, 2005
Slide 1: Chairman's Address and Managing Director's Presentation
He & Limited Biopharmaceuticals for Life 12 October 2005 The Company Announcements Office Australian Stock Exchange Limited 530 Collins St MELBOURNE VIC 3000 Dear Sir/Madam CHAIRMAN’S ADDRESS AND MANAGING DIRECTOR’S PRESENTATION Please find attached copies of the Chairman’s Address and Managing Dire
Slide 2: Chairman's Address - Annual General Meeting
CSL LIMITED CHAIRMAN’S ADDRESS —- ANNUAL GENERAL MEETING 12 OCTOBER 2005 “I am pleased to report that the ongoing integration of CSL’s expanded plasma therapeutics business operations has enabled us to deliver our strongest financial result to date, “ZLB Behring completed a very successful first ful
Slide 3: ZLB Behring and CSL Bioplasma business report
“Based at King of Prussia in Pennsylvania, ZLB Behring has substantial markets in the US, Europe and Japan. ZLB Behring has manufacturing operations in the US, Switzerland and Germany, and regional sales offices in 19 other countries. “ZLB Behring is well positioned to develop its global business th
Slide 4: CSL Pharmaceutical and influenza vaccine centre
“CSL Pharmaceutical sales revenue of $205 million compared favourably with our result for the previous year given a reduction in pharmaceutical distribution activities. “In May 2005, CSL’s new influenza vaccine centre was officially opened in Melbourne. Australia’s first line of defence against infl
Slide 5: Research: ISCOMATRIX adjuvant and antibody fragment delivery
technology to achieve topical delivery of antibody fragments for treating serious eye diseases “In recent years, we have invested significantly in our proprietary ISCOMATRIX adjuvant technology. When formulated with an antigen, an adjuvant increases the quality and strength of the immune response to
Slide 6: Australian Shareholders' Association questions
the after-tax amount of the discount related to inventory in the 2004-05 financial year was USD117m and the value of the anticipated release for the 2005-06 year was also provided being approximately USD40m. “The ASA were also interested in understanding why there appeared to be a disproportionate i
Slide 7: Remuneration, dividend and outlook
“Finally, in respect to the Company’s Remuneration Report, the ASA has asked the Company to make a statement regarding its position on whether it allows executives to hedge their share and option plans through price protection mechanisms currently being offered by a number of banks. I am able to sta
Slide 8: Our thanks to management and staff
OUR THANKS TO MANAGEMENT AND STAFF “Fundamental to our delivering CSL’s best ever financial result has been the successful integration of two plasma therapeutics businesses during the year. Many people have been directly involved in this process, and many others have played their part in making it h
Slide 9: yrs apaneesies
yrs apaneesies ee ee De een Vag, Saas | 1, y gy Lp | A yy ep Ay i g ki - Wye Ge Ly i ey Lo y Le La) Le Lee ee LCC Lo Ly Oe Ly y Ly oe Ly yj oy eg Lo Cy La a PREY: ee Bo > LEY ayes és ay) ee) Le ee iy EN EA, Ly yy y ey I ee ey. LE WL Le | Uy Ye Ye ges YY ey YY II. Wye CL Yee Be y LO Wes Le Goes Py ee
Slide 10: TE EE SEE we pS
TE EE SEE we pS LOO LO uke ee Lee i Poy p nso wey es y Type laps yp Ge, ve . Wee yy ee i Ba eee WD Vise WI, oy) oe iy gy Loy yy js y i ey Le LG Ie ay YE, y Ve y ey Te 4 ye Ye yy y ie LSU OGY US Le a oan ae Lees ie - spec aa sts iy Lae Sy 72 yy Os y i EE he I ey ye, Ys PE EY ey ay TO A i LOIS ie LE L
Slide 11: Net Profit After Tax (pre goodwill)
$M Net Profit After Tax (pre G/Will) -7009 600..- : : [@ Continuous operations Mi Animal Health & JRH contribution 500 + 400 + 300 + 200. - 4100-4 2003 (iti 2004s—i—St—~=~*~=~S 08 Gath Limited
Slide 12: % Net Debt / Net Debt + Equity
% Net Debt / Net Debt + Equity 2003 — 2004. 2005 2S GSb iinites
Slide 13: ZLB Behring
ZLB Behring © ‘Sales AS2, 195m (uss 656m) EBITA A$366m Integration substantially complete ‘Strong Helixate sales | —US IVIG pricing environment improving 2S GSb iinites
Slide 14: Low cost, high yield manufacturing
] ogy iy SI MMM OES eee LOG ey 7 spss yy YES YOU LEE OREO yy Lee LIE EL “Low C Cos et High ' Yield Manufacturi a] Le ELLA spapepesauncaraarenescsnayy LE LL TE, "Maximising Profitab Litres TE Ye LIDIA. erence o ey ee Oe: ae: 7 Up Ga Ee Le pray Ci Ly ip Wy, ore. Le Le Biase iy, ‘oy sae ee LO ee Ly i e
Slide 15: Broad portfolio of products
er Bet Fete ees 1 eery oie Broad portfolio of products. Other 2% 1FV111 20% Immunoglobulins 31% Pd Coag 25%... "Critical Care 17% | GSB Limited
Slide 16: CSL Bioplasma
CSLBioplasma m Sales $208m (+17%) @ Australian business _ | « Plasma Products Agreement now in place = fFVIIL policy. | : * Impact on pdFVII & pdFIX sales oe Kogenate distribution agreement in place. ahead -. of Government tender process. a Asian business - #. Strong demand for ZLB Behring Albumin >
Slide 17: CSL Pharmaceutical
CSL. Pharmaceutical - H Sales $205m ~ Sales steady compared with 2004 — Boosted by additional sale of Fluvax @ Expanded influenza vaccine facility Only facility of its kind in | the southern hemisphere — Opportunity to expand presence in northern hemisphere markets Capacity Approx. 15 -20m doses 2S
Slide 18: CSL Pharmaceutical - Pandemic Preparedness
CSL Pharmaceutical - Pandemic Preparedness m Facilities and resources in place to provide pandemic vaccines for Australia « 3 year contract with Govt. for pandemic preparedness = First pandemic prototype vaccine clinical: trials started in Australia " Results Feb 2006. Depending on results, proceed
Slide 19: GARDASIL - First Phase III Efficacy Study
GARDASIL® - First Ph ase Ill Efficacy Study — - Prevented 100% of HPV 16 +18 Cervical . - pre + non-invasive cancers : 2 years of data 12,200 women in study aged 16 - 26 years Key part of full Phase ill program — Merck anticipates FDA submission i in 4th Qtr 2005 Merck has been granted “fast track -
Slide 20: Cervical Cancer
Cervical Cancer — - Second most common cancer affecting womel Virtually all cases associated with HPV — Greater than 2/, due to types 16+ 18 Globally 500,000 cases diagnosed each year, 300,000 deaths ; @ Prevalence of Cx Cancer 1 ‘4 million cases -world wide - ez Every year in Australia 100,000 wome
Slide 21: Merck & CSL
Merck & CSL. m 1991 CSL initiated research collaboration with — - Prof. lan Frazer, University of Queensland. : 4995 CSL & Merck entered a licence and collaboration agreement m In February 2005 CSL entered into a cross licensing and settlement agreement with — GlaxoSmithKline (GSK) m@ Gardasil will
Slide 22: Group Outlook
Group Outlook _ ao ‘Financial Outlook FY2006™ - Sales revenue maintained in 2006 = R&Di increasing approx. 5% = Effective tax rate between 30 & 35% « EBITA growth approx. 10% = EPS from continuing operations (NEAT pre-goodwil) up approx. 10% * Driven by operations and capital management - Excludes I
Slide 23: The Phased Development of CSL Limited
The Phased Development of CSL Limited _ Enhancements Gath Limited
Slide 24: yrs apaneesies
yrs apaneesies ee ee De een Vag, Saas | 1, y gy Lp | A yy ep Ay i g ki - Wye Ge Ly i ey Lo y Le La) Le Lee ee LCC Lo Ly Oe Ly y Ly oe Ly yj oy eg Lo Cy La a PREY: ee Bo > LEY ayes és ay) ee) Le ee iy EN EA, Ly yy y ey I ee ey. LE WL Le | Uy Ye Ye ges YY ey YY II. Wye CL Yee Be y LO Wes Le Goes Py ee